CROI 2010 Coverage - Highlights by HIV and Hepatitis.com of CROI 2010,San Francisco, CA

You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

Sign up to receive our twice-weekly e-Newsletter

HIV and Hepatitis.com Coverage of the
17th Conference on Retroviruses and
Opportunistic Infections (CROI 2010)
February 16 - 19, San Franciso, California

The material posted on HIV and Hepatitis.com about CROI 2010 is not approved by nor is it a part of CROI 2010.

	Library of Slides and Posters
	HIV/AIDS Articles
	HIV/HCV and HIV/HBV Coinfection Articles

HIV/AIDS Articles

LAUNCH CROI 2010 TALKING SLIDES UPDATE

Even Low-level, Short-term Detectable Viral Load Raises the Risk of Virological Treatment Failure and Death

Vitamin D Deficiency Is Widespread Among People with HIV in U.S., Europe, and Africa

ART Intensification with Maraviroc (Selzentry) or Raltegravir (Isentress) May Improve Immune Activation and Inflammation

VIRxSYS Lentivirus Vector HIV Vaccine Reduces Viral Load in Monkey Study

Prompt Testing and Expanded Treatment Linked to Reduce HIV Incidence in San Francisco, Washington DC, and Vancouver

Early Indicators of Atherosclerosis in People with HIV Are Linked to Inflammation, Improve with Antiretroviral Therapy

Risk Factors for Neurocognitive Impairment among People with HIV

Inflammation and Immune Activation Linked to Increase Mortality Risk in People with

Elevated Inflammatory Biomarkers Are Associated with Progression to AIDS and Death despite Viral Suppression

Poor Response to Hepatitis B Vaccine Predicts HIV Disease Progression

Two European Studies Find Some People with HIV Who Start Treatment Early Can Reach Normal Life Expectancy

Daily Treatment with Valganciclovir Reduces Immune Activation in HIV Positive People with Cytomegalovirus

Chronic Kidney Disease Linked to Tenofovir (Viread) in EuroSIDA Study

HIV Infection and HIV/HCV Coinfection Increased Risk of Strokes in Veterans Study

LEDGF Integrase Inhibitors and Capsid Assembly Inhibitors Offer New Approaches for Blocking HIV Replication

ACTG 5202 Shows Abacavir/lamivudine and Tenofovir/emtricitabine Provide Similar HIV Suppression at Low Viral Loads

ACTG 5202 Sub-study Finds Lipoatrophy Uncommon, Antiretroviral Drugs Have Varying Effects on Bone and Body Fat

Early Antiretroviral Therapy Reduces HIV Transmission in Discordant Heterosexual Couples

Once-daily Boosted Darunavir (Prezista) Works as Well as Twice-daily for Treatment-experienced Patients

Quitting Smoking Lowers Risk of Cardiovascular Disease in People with HIV

HIV Raises Lung Cancer Risk, but Smoking Is a Much Stronger Predictor

Research Sheds New Light on HIV in the Gut

Investigational Drug TBR-652 Demonstrates Dual Activity against CCR5 and CCR2 Co-receptors

Treatment Intensification with Maraviroc (Selzentry) Did Not Raise CD4 Cell Counts in Small Study

Poor CD4 Cell Recovery on Antiretroviral Therapy Is Linked to Late Treatment, Leads to Adverse Outcomes

Gilead's "Quad" Pill Matches Atripla, New Booster Cobicistat (GS 9350) Looks Good with Atazanavir (Reyataz)

Does Liver Fibrosis Progress Faster in People Who Have HIV When They Acquire Hepatitis C?

The U.S. HIV Research Agenda and the Future of PEPFAR

Vicriviroc Fails to Beat Stiff Competition, Merck Will Not File for Treatment-experienced Approval

	HIV/HCV and HIV/HBV Coinfection Articles
	Spontaneous Clearance and Successful Treatment of Hepatitis C Linked to Better CD4 Cell Recovery
	HIV/HBV Coinfected People at High Risk for Disease Progression During Antiretroviral Treatment Interruption
	IL28B Gene Variation Linked to Spontaneous Clearance and Treatment Response in HIV/HCV Coinfected People
	HIV/HBV and HIV/HCV Coinfected People with Impaired Liver Function and Inflammation Have Higher Risk of Non-AIDS Death
	Poor Response to Hepatitis B Vaccine Predicts HIV Disease Progression
	Boys with Chronic Hepatitis B May Experience HBeAg Seroconversion and Reduced HBV Viral Load at Puberty
	HIV Infection and HIV/HCV Coinfection Increased Risk of Strokes in Veterans Study
	HIV/HBV and HIV/HCV Coinfected Patients in Africa Have Slower CD4 Recovery on Antiretroviral Therapy, but Not Increased Mortality
	More Evidence of Rapid Liver Disease Progression in HIV/HCV Coinfected People, but Antiretroviral Therapy Lowers Risk
	Abacavir (Ziagen) Does Not Compromise Effectiveness of Hepatitis C Treatment, but Zidovudine (Retrovir) May Reduce Response
	Liver Toxicity in an International Cohort of HIV/HBV Coinfected Patients on Long-term Antiretroviral Therapy
	Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
	Leakage of Gut Bacteria Linked to Poor Hepatitis C Treatment Response in HIV/HCV Coinfected Patients
	Hepatitis B Virus Genotype G Associated with Increased Fibrosis in HIV/HBV Coinfected People, but Blacks Fare Better
	Hepatitis C Virus Can Survive in Syringes Up to 2 Months under Favorable Conditions
	Sustained Response to Interferon Reduces both Liver-related and AIDS-related Disease and Death in HIV/HCV Coinfected Patients
	Endothelial Dysfunction Is Worse in People with HIV/HCV Coinfection, but Improves with Sustained Response to Hepatitis C Treatment
	HBV DNA Not Detected in Semen of Men with Chronic Hepatitis B Successfully Treated with Nucleotide Analogs
	Shorter Treatment May Be Adequate for Genotype 1 Hepatitis C If Started during Acute Infection
	Does Liver Fibrosis Progress Faster in People Who Have HIV When They Acquire Hepatitis C?

	Library of Slides and Posters
	Fat Tissue Distribution Changes in HIV-infected Patients with Viral Suppression Treated with Darunavir/ritonavir (DRV/r) monotherapy versus 2 NRTIs + DRV/r in the MONOI-ANRS 136 Randomized Trial : Results at 48 weeks M Valantin and others. CROI 2010.
	Darunavir Concentrations in Seminal Plasma in patients receiving Darunavir/ritonavir(DRV/r) monotherapy: a MONOI-ANRS 136 substudy L Niclot and others. CROI 2010.
	The Single-Tablet, Fixed-Dose Regimen of Elvitegravir/GS-9350/Emtricitabine/Tenofovir DF (Quad) Achieves a High Rate of VirologicSuppression and GS-9350 is an Effective Booster C Cohen and others. CROI 2010.
	Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir when Combined in Treatment Experienced Patients:a Substudy of the ANRS 139 TRIO A Barrail-Tran and others. CROI 2010.
	The Prevalence of Darunavir Associated Mutations in PI-naive and PI-experienced HIV-1 Infected Children in the UK K Boyd and others. CROI 2010.
	Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified Through Correlation with Matched Phenotype M Haddad and others. CROI 2010.
	The Binary Protease Inhibitor, Darunavir, Has a High Genetic Barrier to the Emergence of Resistant HIV-1 Variants Y Koh and others. CROI 2010.
	Resistance Associated Mutations to Etravirine (TMC-125) in Antiretroviral Naïve Patients infected with non-B HIV-1 subtypes A Maiiga and others. CROI 2010.
	Darunavir (DRV) concentrations exceed the Protein-corrected (PC) EC50 for wild type HIV in the semen of HIV-1 infected Men S Taylor and others. CROI 2010.
	Discovery of Potent HIV-1 Capsid Assembly Inhibitors S Titolo and others. CROI 2010.
	Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients E Gotuzzo and others. CROI 2010.
	Metabolic Profiles and Body Composition Changes in Treatment-Naïve HIV-Infected Patients Treated with Raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 96-Week Follow-Up E DeJesus and others. CROI 2010.
	Hepatic Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B (HBV) and/or C (HCV) Virus J Rockstroh and others. CROI 2010.
	Sustained Antiretroviral Effect of Raltegravir at Week 156 in the BENCHMRK Studies, and Exploratory Analysis of Late Outcomes based on Early Virologic Responses J Eron and others. CROI 2010.
	A Pharmacokinetic Comparison of Adult and Pediatric Formulations of Raltegravir (RAL) in Healthy Adults D Brainard and others. CROI 2010.
	Pharmacokinetic (PK), Safety and Efficacy Data on Cohort IIA; youth aged 6-11 from IMPAACT P1066: A Phase I/II Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth S Nachman and others. CROI 2010.

CROI 2010 Coverage